Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$7.84 - $16.79 $1.06 Million - $2.26 Million
134,621 Added 1289.6%
145,060 $1.21 Million
Q1 2024

May 15, 2024

BUY
$13.2 - $17.76 $137,794 - $185,396
10,439 New
10,439 $185,000
Q1 2023

May 15, 2023

BUY
$7.36 - $12.72 $130,161 - $224,953
17,685 New
17,685 $141,000
Q2 2022

Aug 15, 2022

BUY
$4.66 - $13.96 $69,037 - $206,817
14,815 New
14,815 $81,000
Q1 2022

May 16, 2022

SELL
$11.89 - $24.68 $101,017 - $209,681
-8,496 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$24.14 - $35.18 $205,093 - $298,889
8,496 New
8,496 $211,000
Q3 2021

Nov 15, 2021

SELL
$27.38 - $42.21 $543,684 - $838,163
-19,857 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$26.34 - $46.62 $301,672 - $533,938
-11,453 Reduced 36.58%
19,857 $574,000
Q1 2021

May 17, 2021

BUY
$45.96 - $68.02 $1.05 Million - $1.55 Million
22,788 Added 267.4%
31,310 $1.59 Million
Q4 2020

Feb 16, 2021

SELL
$13.72 - $51.57 $108,278 - $406,990
-7,892 Reduced 48.08%
8,522 $414,000
Q3 2020

Nov 16, 2020

SELL
$10.54 - $18.47 $176,576 - $309,427
-16,753 Reduced 50.51%
16,414 $290,000
Q2 2020

Aug 14, 2020

SELL
$10.37 - $20.64 $126,628 - $252,035
-12,211 Reduced 26.91%
33,167 $604,000
Q1 2020

May 15, 2020

SELL
$9.63 - $17.14 $68,796 - $122,448
-7,144 Reduced 13.6%
45,378 $550,000
Q4 2019

Feb 14, 2020

SELL
$7.2 - $13.2 $194,443 - $356,479
-27,006 Reduced 33.96%
52,522 $692,000
Q3 2019

Nov 14, 2019

BUY
$8.95 - $15.72 $167,714 - $294,577
18,739 Added 30.83%
79,528 $712,000
Q2 2019

Aug 14, 2019

BUY
$14.61 - $22.45 $386,478 - $593,869
26,453 Added 77.04%
60,789 $964,000
Q1 2019

May 15, 2019

BUY
$14.24 - $22.28 $488,944 - $765,006
34,336 New
34,336 $645,000

Others Institutions Holding SRRK

About Scholar Rock Holding Corp


  • Ticker SRRK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,640,600
  • Market Cap $2.35B
  • Description
  • Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clini...
More about SRRK
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.